Clinical Trial Update: Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) [Phase 1, Phase 2]

View source ↗

Summary

This Phase I/II trial of BN-Brachyury Vaccine, M7824, N-803, and Epacadostat in metastatic castration-resistant prostate cancer has completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Non-metastatic Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• BN-Brachyury Vaccine
• Epacadostat (epacadostat)
• M7824 (bintrafusp alfa)
• N-803

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-06-08